Latest / Stock Movers / JPMorgan and Wells Fargo Report; JNJ and UNH Earnings
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio. News. The Stock Movers Report.
- 0:10Speaker 1: Your roundup of companies making moves in the stock market.
- 0:13Speaker 1: Harnessing the power of Bloomberg data.
- 0:16Speaker 2: Let's take a look at some stocks on the move today.
- 0:18Speaker 2: I'm Nathan Hager, joined by Bloomberg's Dan Curtis on the
- 0:21Speaker 2: kickoff of earnings season in earnest. We're starting to hear
- 0:25Speaker 2: from the big banks. They keep making money, but apparently
- 0:27Speaker 2: they're not making any money. not at the bar that
- 0:29Speaker 2: Wall Street set. Start us off with JPMorgan Chase. Dan,
- 0:33Speaker 2: good morning.
- 0:33Speaker 3: Good morning. JPMorgan Chase, those shares down over 3% in
- 0:37Speaker 3: the pre-market trading under ticker JPM. The company's revenue came
- 0:41Speaker 3: in at $ 50. 9 billion. That was slightly below estimates. A
- 0:45Speaker 3: big focus here is fixed sales, so fixed income commodities, currencies.
- 0:49Speaker 3: The sales and trading revs there were $ 5. 37 billion. That
- 0:53Speaker 3: was well below the estimated $ 6 billion figure. This was
- 0:58Speaker 3: a drop from the same period last year, the first
- 1:00Speaker 3: decline in over two years for the business. Currencies and
- 1:04Speaker 3: EM helped keep the drop from being bigger there. So
- 1:08Speaker 3: it's looking like it's setting a low bar for the
- 1:11Speaker 3: FIC business for the other banks as we await to
- 1:14Speaker 3: hear some other bulge bracket firms. Other figures that we got,
- 1:17Speaker 3: investment banking revenue, $ 3. 1 billion. That was a miss. Equity
- 1:21Speaker 3: sales and trading did come in stronger than estimates, nearly
- 1:24Speaker 3: $ 5 billion. Net interest income also came in stronger than
- 1:28Speaker 3: estimates at $ 27.
- 1:30Speaker 1: 2 billion.
- 1:31Speaker 3: It seems here FIC, the big focus, and that will
- 1:34Speaker 3: continue to be as we get more bank earnings this season.
- 1:37Speaker 2: Well, is that the focus, as we also heard this
- 1:39Speaker 2: morning from Wells Fargo, and that stock's on the decline
- 1:43Speaker 2: in the pre-market as well?
- 1:44Speaker 3: That's right. So Wells Fargo ticker WFC down 1.4%. This
- 1:49Speaker 3: is more of a consumer-oriented business. The net interest income
- 1:53Speaker 3: of about $ 12. 5 billion came in matching estimates, and the
- 1:57Speaker 3: company sees another about half a billion rise in the
- 2:00Speaker 3: current quarter. It's forecasting $ 13 billion for the fourth quarter.
- 2:04Speaker 3: Total revenue, though, $ 21. 9 billion was below estimates. and non-interest
- 2:10Speaker 3: expenses fell 1%. The company cited an 8% cut in headcount,
- 2:15Speaker 3: lower severance expenses than expected. So a little bit of a,
- 2:19Speaker 3: you know, pairing their costs, but overall total revenue missing estimates.
- 2:25Speaker 2: Okay, so while we wait for some of those other
- 2:27Speaker 2: banks to report, we've also heard from a number of
- 2:30Speaker 2: other names, including UnitedHealth Group. Looks like they put out
- 2:34Speaker 2: some results that investors really.
- 2:36Speaker 1: Seem to like.
- 2:37Speaker 3: Yeah, finally getting to the green spot on my screen. UnitedHealth, UNH,
- 2:40Speaker 3: up 2.2%. The company's raising its profit outlook for the
- 2:44Speaker 3: year as costs ease. It now sees full-year EPS of
- 2:48Speaker 3: at least $ 20. 50. That's 50 cents higher than the previous guidance.
- 2:53Speaker 3: That's on top of third quarter top and bottom line
- 2:55Speaker 3: figures that beat estimates. And a key measure that we're
- 2:58Speaker 3: looking at is one where the company spent $ 0. 88 on
- 3:02Speaker 3: medical claims per dollar collected in premiums. So that was
- 3:05Speaker 3: less than expected. They paid out a little bit less
- 3:07Speaker 3: in premiums per dollar earned. So that's helping to add
- 3:10Speaker 3: to the bullishness. The company also benefited from $ 610 million
- 3:14Speaker 3: in favorable reserves. And that just reflects money set aside
- 3:17Speaker 3: for medical claims that wasn't ultimately needed. So fewer medical
- 3:21Speaker 3: claims than expected.
- 3:22Speaker 2: We all started from Johnson & Johnson. This one looked
- 3:24Speaker 2: like a beat, but the stock's lower right now.
- 3:26Speaker 3: What's going on? That's right. So J & J, it's
- 3:29Speaker 3: down 3% in the pre-market ticker J & J. And
- 3:33Speaker 3: a little bit of just context to this, the stock
- 3:35Speaker 3: was up 27%. into the earnings report for the year.
- 3:39Speaker 3: So it's had a very strong run into these figures.
- 3:41Speaker 3: So Wall Street has set a high bar. The company
- 3:44Speaker 3: itself is raising profit guidance on demand for newer drugs
- 3:47Speaker 3: for cancer and autoimmune diseases, but that's countering anemic growth
- 3:51Speaker 3: in medical device business. The J & J CFO said
- 3:54Speaker 3: it's leaning towards orthopedic unit spinoff instead of sale. That's
- 3:58Speaker 3: from part of that struggling medical device units. But overall,
- 4:01Speaker 3: third quarter top line matched estimates. Adjusted earnings per share
- 4:05Speaker 3: came in above estimates. That figure, pretty complicated, but it's
- 4:09Speaker 3: still a beat.
- 4:10Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 4:14Speaker 1: us throughout the day for the latest roundup of companies
- 4:17Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 4:21Speaker 1: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 4:26Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:29Speaker 1: Business app.